ESTRELLA IMMUNOPHARMA, INC. Increase (Decrease) in Accrued Liabilities
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Increase (Decrease) in Accrued Liabilities of -$4.13 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-05-18
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$4.13M, a 404.05% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$500.00K, a 1463.62% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $4.13M, a 50.22% increase year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-06-30 was $4.63M.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $9.61M.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$18.00K, a 181.82% decline from fiscal 2023.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $22.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$4.13M 10-Q · filed 2026-05-18 | -$4.63M derived: sum of 2 quarters · filed 2026-05-18 | -$500.00K derived: sum of 3 quarters · filed 2026-05-18 | $4.13M derived: sum of 4 quarters · filed 2026-05-18 |
| 2025-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $3.63M derived: sum of 2 quarters · filed 2026-03-18 | $8.25M derived: sum of 3 quarters · filed 2026-03-18 | $9.61M 10-K · filed 2026-03-18 |
| 2025-09-30 | $4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $8.75M derived: sum of 2 quarters · filed 2025-11-12 | $10.11M 10-Q · filed 2025-11-12 | $10.14M derived: sum of 4 quarters · filed 2026-05-18 |
| 2025-06-30 | $4.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $5.98M 10-Q · filed 2025-08-12 | $6.02M derived: sum of 3 quarters · filed 2026-05-18 | $8.76M derived: sum of 4 quarters · filed 2026-05-18 |
| 2025-03-31 | $1.36M 10-Q · filed 2026-05-18 | $1.39M derived: sum of 2 quarters · filed 2026-05-18 | $4.14M derived: sum of 3 quarters · filed 2026-05-18 | $4.14M derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | $36.67K derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-18 | $2.78M 10-K · filed 2026-03-18 | $2.78M derived: sum of 3 quarters · filed 2026-03-18 | $2.78M derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-09-30 | $2.75M 10-Q · filed 2024-11-14 | $2.75M derived: sum of 2 quarters · filed 2025-08-12 | $2.74M 10-Q · filed 2025-11-12 | $2.73M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$2.00K 10-Q · filed 2025-08-12 | -$20.00K derived: sum of 3 quarters · filed 2025-08-12 | -$18.00K 10-KT · filed 2025-03-25 |
| 2024-03-31 | -$2.00K 10-Q · filed 2025-05-14 | -$20.00K derived: sum of 2 quarters · filed 2025-05-14 | -$18.00K 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | -$16.00K 10-Q · filed 2024-02-14 | ||
| 2023-09-30 | $2.00K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $22.00K 10-K · filed 2024-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |